Acceder

Bloque I. Mecanismo de acción de los analgésicos

Clasificación de los analgésicos: Coadyuvantes y coanalgésicos

Coordinado por: Dr. Ignacio Velazquez

Fuentes Bibliográficas

  1. Engel GL. The clinical application of the biopsychosocial model. Am J Psychiatry. 1980; 137(5):535-544.
  2. Vesalius A, Huard P, Imbault-Huart M, Andrés Vesalio. Iconografía Anatómica. Barcelona: Laboratorios Beecham; 1983.
  3. Rey R. Pain in the Renaissance. En: Rey R, ed., The History of Pain. Massachusetts: Harvard University Press; 1998:50-53.
  4. López Piñero J, Navarro V, Portela E. La Revolución Científica. 6a ed. Madrid: Biblioteca Historia; 1989:158-160.
  5. Rey R. The "Anodyne" Remedies: From the Ligature to "Sweet Vitriol". En: Rey R, ed. The History of Pain. Massachusetts: Harvard University Press; 1998:64-69.
  6. Merskey H. Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms. Pain Suppl. 1986; 3(Supl. 3):S1-226.
  7. Merskey H, Bogduk N. Classification of chronic pain. Classification of chronic pain syndromes and definitions of pain terms. International Association for the Study of Pain. Task force on taxonomy. IASP press. 1994.
  8. Soucase B. Monsalve V. Soriano JF. Afrontamiento del dolor crónico: el papel de las variables de valoración y estrategias de afrontamiento en la predicción de la ansiedad y la depresión en una muestra de pacientes con dolor crónico. Rev Soc Esp Dolor. 2005; 12(1):8-16.
  9. Lorca GJ, Muriel C, González Tablas MM, Díez MA. Relación entre características del dolor crónico y niveles de depresión. Rev Soc Esp Dolor. 2007; 14(1):26-35.
  10. Marcelo G. Pain and sleep: two biological present conditions. Boletín El Dolor. 2005; 14(1):30-32.
  11. 8. Bonica JJ. Neurophysiologic and Pathologic Aspects of Acute and Chronic Pain. Archives of Surgery. 1977; 112(6):750-761.
  12. Blanco C. Sir Charles Sherrington y la naturaleza de lo mental. Contrastes. Revista Internacional de Filosofía. 2014; 19(2):207-227.
  13. Arendt-Nielsen L, Nie H, Laursen M, et al. Sensitization in patients with painful knee osteoarthritis. Pain. 2010; 149(3):573-581.
  14. 10. Graven-Nielsen T, Arendt-Nielsen L. Peripheral and central sensitization in musculoskeletal pain disorders: An experimental approach. Curr Rheumatol Rep. 2002; 4(4):313-321.
  15. Suokas A, Walsh D, McWilliams D et al. Quantitative sensory testing in painful osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartil. 2012; 20(10):1075-1085.
  16. Gwilym S, Filippini N, Douaud G, Carr A, Tracey I. Thalamic atrophy associated with painful osteoarthritis of the hip is reversible after arthroplasty: A longitudinal voxel-based morphometric study. Arthritis & Rheumatism. 2010; 62(10):2930-2940.
  17. Goicoechea C, Martín M. Mecanismos periféricos y centrales del dolor. Reumatología Clínica. 2006; 2(1):S5-S9.
  18. Marchand F, Perretti M, McMahon S. Role of the Immune system in chronic pain. Nat Rev Neuroscience. 2005; 6(7):521-532.
  19. Tsuda M, Inoue K, Salter M. Neuropathic pain and spinal microglia: a big problem from molecules in ‘small’ glia. Trends Neurosci. 2005; 28(2):101-107.
  20. Inglis JJ, Nissim A, Lees DM, Hunt SP, Chernajovsky Y, Kidd BL. The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation. Arthritis Res Ther. 2005; 7(4):R807-16.
  21. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer. 1987; 59(4):850-856.
  22. Torres LM. De la escalera analgésica al ascensor. Rev Soc Esp Dolor. 2002; 9(1):289-290.
  23. Schnider T, Minto C. Pharmacokinetics and pharmacodynamic principles of drug action. En: Evers A, Merlyn M, ed. Anesthetics Pharmacology: Physiological Principles and Clinical Practice. 1a ed. Edimburgo: Churchill Livingston; 2004:3-21.
  24. Wilson K. Implicaciones psicológicas del dolor crónico. En: Prithivi Raj P, ed. Tratamiento Práctico Del Dolor. 3a ed. Madrid: Harcourt; 2002:332-345.
  25. Rivera-Ordóñez A. AINES: Su mecanismo de acción en el sistema nervioso central. Revista Mexicana de Anestesiología; 29(1):36-40.
  26. Hours JE, Redín A, Pueyo MG, Ferreres I, Garrido C. Estudio de la utilización de analgésicos en el tratamiento de procesos dolorosos ocasionales, leves y moderados, en farmacias comunitarias (estudio FANAL). Pharmaceutical Care España. 2007; 9(1):10-8.
  27. González Iglesias J. Historia de la Anestesia. Madrid: Editores Médicos; 1995.
  28. Haeger K. Historia de la cirugía. Madrid: Editorial Raíces; 1993.
  29. Furst D. Are there differences among nonsteroidal anti-inflammatory drugs? Comparing acetylated salicylates and nonacetylated nonsteroidal anti-inflammatory drugs. Arthitis Rheum. 1994; 37(1):1-9.
  30. Hardman J, Limbird L, Molinoff P, et al. Las Bases Farmacológicas de La Terapéutica. México: McGraw-Hill Interamericana; 1996:661-669.
  31. Day R. A Randomized Trial of the Efficacy and Tolerability of the COX-2 Inhibitor Rofecoxib vs Ibuprofen in Patients with Osteoarthritis. Arch Intern Med. 2000;160(12):1781-178.
  32. Pepper G. Nonsteroidal anti-inflammatory drugs. New perspectives on a familiar drug class. Nurs Clin North Am. 2000; 35(1):223-244.
  33. Vane J. Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs. Nat New Biology. 1971; 231(25):232-235.
  34. Crofford LJ. Nonsteroidal anti-inflammatory drugs. En: Harris ED, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, Sledge CB, eds. Kelley.
  35. Ferreira S. Prostaglandins: Peripheral and Central Analgesia. Adv Pain Res Ther. 1983; 5(1):627-634.
  36. Ferreira S. The Role of Interleukins and Nitric Oxide in the Mediation of Inflammatory Pain and its Control by Peripheral Analgesics. Drugs.1993; 46(Supl. 1):1-9.
  37. Flossmann E, Rothwell P. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369(9573):1603-1613.
  38. Rostom A, Dubé C, Lewin G, et al. Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007; 146(5):376-389.
  39. Brooks P, Day R. Nonsteroidal anti-inflammatory drugs: Differences and similarities. N Eng J Med. 1991; 324(24):1716-1725.
  40. Peña Forcada E, Saiz Cantero C, Romero Atanes M, Sánchez Sánchez M, Sarrion Bosque A. Gastropatía por antiinflamatorios no esteroideos. SEMERGEN - Medicina de Familia. 2008; 34(10):502-506.
  41. Brooks P. Use and Benefits of Nonsteroidal Anti-inflammatory Drugs. Am J Med. 1998;104(3A):9S-13S.
  42. Lanas A. Aspectos relevantes sobre efectos secundarios gastrointestinales asociados a los AINE: Últimas novedades presentadas en gastroenterología. Gastroenterol Hepatol. 2005; 3(1):10-4.
  43. Lanas A, Garcia-Rodriguez L, Arroyo M et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006; 55(12):1731-1738.
  44. Hernández-Dı́az S, Garcı́a-Rodrı́guez L. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med. 2001; 110(Supl. 3):20S-27S.
  45. Jouzeau J, Terlain B, Abid A, Nédélec E, Netter P. Cyclo-Oxygenase Isoenzymes. Drugs. 1997; 53(4):563-582.
  46. Bombardier C, Laine L, Reicin A, et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. VIGOR Study Group. N Engl J Med. 2000; 343(21):1520-1528
  47. McGettigan P, Henry D. Cardiovascular Risk and Inhibition of Cyclooxygenase. JAMA. 2006; 296(13):1633-1644.
  48. Catella-Lawson F, Crofford L. Cyclooxygenase inhibition and thrombogenicity. Am J Med. 2001; 110(Supl. 3):28S-32S.
  49. Johnson A. Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis. Ann Intern Med. 1994;121(4):289-300.
  50. Cannon C, Curtis S, Bolognese J, Laine L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J. 2006; 152(2):237-245.
  51. Agencia Española de Medicamentos y Productos Sanitarios. Actualización sobre los riesgos de tipo aterotrombótico de los coxibs y AINE tradicionales. Nota informativa 2006/10. Fecha de publicación: 26 de octubre de 2006. Consultado el 19 de marzo de 2018.
  52. Antman E, Bennett J, Daugherty A, Furberg C, Roberts H, Taubert K. Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement from the American Heart Association. Circulation. 2007; 115(12):1634-1642.
  53. Musu M, Finco G, Antonucci R, et al. Acute nephrotoxicity of NSAID from the foetus to the adult. Eur Rev Med Pharmacol Sci. 2011; 15(12):1461-1472.
  54. Dinchuk J, Car B, Focht R, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995; 378(6555):406-409.
  55. Hao C, Breyer M. Physiological Regulation of Prostaglandins in the Kidney. Annu Rev Physiol. 2008; 70(1):357-377
  56. Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010; 77(11):956-961.
  57. Praga M, Sevillano A, Auñón P, González E. Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant. 2015; 30(9):1472-1479.
  58. Muriithi A, Nasr S, Leung N. Utility of Urine Eosinophils in the Diagnosis of Acute Interstitial Nephritis. Clin J Am Soc Nephrol. 2013;8(11):1857-1862.
  59. Farré M, Abanades S, Álvarez Y, Barral D, Roset PN. Paracetamol. Dolor. 2004; 19(1):5-15.
  60. Forrest J, Clements J, Prescott L. Clinical Pharmacokinetics of Paracetamol. Clin Pharmacokinet. 1982; 7(2):93-107.
  61. Roca-Vinardell A, Ortega-Alvaro A, Gibert-Rahola J, Micó J. The Role of 5-HT1A/B Autoreceptors in the Antinociceptive Effect of Systemic Administration of Acetaminophen. Anesthesiology. 2003; 98(3):741-747.
  62. Routeledge P, Vale J, Bateman D, Jones A, Judd A, Thomas S, et al. Paracetamol (acetaminophen) poisoning. BMJ. 1998; 317(7173):1609-1610.
  63. Rumack B. Acetaminophen Hepatotoxicity: The First 35 Years. J Toxicol: Clin Toxicol. 2002; 40(1):3-20.
  64. Prescott L. Paracetamol, alcohol and the liver. Br J Clin Pharmacol. 2001; 49(4):291-301.
  65. Treggiari M, Kleger G, Roux-Lombard P, et al. Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response. Intensive Care Med. 2004; 30(3):401-407.
  66. Flórez J. Farmacología Humana. 5a ed. Barcelona: Elsevier Masson; 2008.
  67. Buitrago-González T, Calderón-Ospina C, Vallejos-Narváez Á. Dipirona: ¿Beneficios subestimados o riesgos sobredimensionados? Revisión de la literatura. Revista Colombiana de Ciencias Químico-Farmacéuticas. 2014; 43(1):173-195.
  68. Bonica JJ. History of pain concepts and therapies. The Management of Pain. 2a ed. Malvern: Lea & Febiger; 1990.
  69. Pérez J, Abejón D, Ortiz JR, Pérez JR. El dolor y su tratamiento a través de la historia. Rev. Soc. Esp. del Dolor. 2005; 12(6):373-384.
  70. López JM. La medicina en la historia. Madrid. 1a ed. Madrid: La Esfera de los Libros; 2002:717.
  71. Cox BM, Opheim KE, Teschemacher H, Goldstein A. A peptide-like substance from the pituitary that acts like morphine: Purification and properties. Life Sci. 1975; 16(12):1777-1782.
  72. Villarejo M, Murillo-Zaragoza JR, Alvarado-Hernández H. Farmacología de los agonistas y antagonistas de los receptores opioides. Educación e Investigación Clínica. 2000; 1(2):106-137.
  73. Mucio S, Miller C, Sánchez E, León M. El receptor ORL-1 y su péptido endógeno, la nociceptina/orfanina FQ: Nuevos miembros de la familia de los opioides. Salud Mental. 2001; 24(6):43-54.
  74. Salvador E, Aliaga L. Combinación de opioides. Rev Soc Esp Dolor. 2016; 23(3): 159-163.
  75. Snyder S. Opiate Receptors and Internal Opiates. Sci Am. 1977; 236(3):44-57.
  76. Valdivielso A. Farmacocinética y farmacodinamia de los opiáceos. Dolor. 1997; 12(Supl. 3):13-16.
  77. Rang HP, Dale MM, Ritter JM, Moore PK. Farmacología. 5ª ed. Madrid: Elsevier; 2004:562-583.
  78. Flórez J, Faura CC. Farmacología de los analgésicos opioides. En: Aliaga L, Baños JE, de Barutell C, Molet J, Rodríguez de la Serna, eds. Tratamiento del dolor. Teoría y práctica. 2ª ed. Barcelona: Publicaciones Permanyer; 2002:85-109.
  79. Smith H. The Metabolism of Opioid Agents and the Clinical Impact of Their Active Metabolites. Clin J Pain. 2011; 27(9):824-838.
  80. Pergolizzi Jr J, Labhsetwar S, Puenpatom R, Joo S, Ben-Joseph R, Summers K. Exposure to Potential CYP450 Pharmacokinetic Drug-Drug Interactions among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions. Pain Practice. 2010; 11(4):325-336.
  81. Smith H. Opioid Metabolism. Mayo Clin Proc. 2009; 84(7):613-624.
  82. Mather L. Clinical pharmacokinetics of analgesic drugs. En: Raj PP, ed. Practical Management of Pain. 2ª ed. St Louis: Mosby Elsevier; 1992.
  83. Gudin J. Opioid Therapies and Cytochrome P450 Interactions. J Pain Symptom Manage. 2012; 44(Supl. 6):S4-S14
  84. Lowenstein E, Hallowell P, Levine F, Daggett W, Austen W, Laver M. Cardiovascular Response to Large Doses of Intravenous Morphine in Man. N Engl J Med. 1969; 281(25):1389-1393
  85. Rosow C, Moss J, Philbin D, Savarese J. Histamine Release during Morphine and Fentanyl Anesthesia. Anesthesiology. 1982; 56(2):93-96.
  86. Vega R. Opioides: Neurobiología, usos médicos y adicción. Elementos. 2005; 60(12):11-23.
  87. Collado F, Torres LM. Farmacología de los opioides. Rev. Soc. Esp. Dolor. 1999; 6(Supl. 4):3-16.
  88. Aliaga L. Tratamiento del dolor: Teoría y práctica. 2ª ed. Barcelona: Permanyer; 2002:85-112.
  89. Isla A, Cortázar JF, Arizmendi L, et al. Avances en el tratamiento farmacológico del dolor crónico: opioides. Gac Med Bilbao. 2007; 104:141-147.
  90. Torres LM, Martínez J, Contreras D. Fentanilo TTS: 3 años de experiencia clínica en Unidades de Dolor. Rev Soc Esp Dolor. 2002; 9:217-228.
  91. Skaer TL. Transdermal opioids for cancer pain. Health Qual Life Outcomes. 2006; 31(4):24.
  92. Fine P, Streisand J. A Review of Oral Transmucosal Fentanyl Citrate: Potent, Rapid and Noninvasive Opioid Analgesia. J Palliat Med. 1998; 1(1):55-63.
  93. Portenoy R, Taylor D, Messina J, Tremmel L. A Randomized, Placebo-controlled Study of Fentanyl Buccal Tablet for Breakthrough Pain in Opioid-treated Patients With Cancer. Clin J Pain. 2006; 22(9):805-811
  94. Dale O, Hjortkjaer R, Kharasch E. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002; 46(7):759-770
  95. Nalamachu S, Hassman D, Wallace M, Dumble S, Derrick R, Howell J. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin. 2011; 27(3):519-530.
  96. Porta-Sales J, Garzón C, Julíà J, Casals M. Dolor irruptivo en cáncer. Med Clin (Barc). 2010; 135(6):280-285.
  97. Vara FJ, García EJ, Garzón N, Centeno C. El uso de metadona en el tratamiento del dolor del enfermo terminal. Libro de Abstract del V Congreso de la Sociedad Española de Dolor. Arán Ediciones; 2002:118-9.
  98. Davis M, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer. 2001; 9(2):73-83.
  99. La Rosa C, Mather L, Morgan D. Pethidine binding in plasma: effects of methodological variables. Br J Clin Pharmacol. 1984; 17(4):411-415
  100. Paech M, Anaes C, Moore J, Evans S. Meperidine for Patient-controlled Analgesia after Cesarean Section Intravenous Versus Epidural Administration. Anesthesiology. 1994; 80(6):1268-1276.
  101. Torres LM. Uso, indicaciones y experiencia con Buprenorfina en parche transdérmico. Dolor. 2003; 18(2):109-114.
  102. Aizpurua I, Ayerdi M, Fernández J, et al. Buprenorfina transdérmica. Comité de evaluación de nuevos medicamentos. Osakidetza. 2003; 76.
  103. Gupta S, Sathyan G. Advances in the long-term Management of Chronic Pain: Recent Evidence with OROS Hydromorphone, a Novel, Once-Daily, Long-Acting Opioid Analgesic. Providing Constant Analgesia with OROS Hydromorphone. J Pain Symptom Manage. 2007; 33(Supl. 2):S19-S24.
  104. Sathyan G, Xu E, Thipphawung HS, et al. Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. BMC Clin Pharmacol. 2007; 7:3.
  105. Hale M, Tudor I, Khanna S, Thipphawong J. Efficacy and tolerability of once-daily OROS® hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: Results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther. 2007; 29(5):874-888.
  106. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic Efficacy and Safety of Oxycodone in Combination With Naloxone as Prolonged Release Tablets in Patients With Moderate to Severe Chronic Pain. Journal Pain. 2008; 9(12):1144-1154.
  107. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther. 1992; 260(1):275-85.
  108. Dayer P, Desmeules J, Collart L. Pharmacologie du tramadol. Drugs. 1997; 53(Sup. 2):18-24.
  109. Gentilli ME, Chauvin M. Tramadol et prise en charge de la douleur. Conférences d’Actualisation. 2004; 715-722.
  110. Sousa A, Ashmawi H. El efecto analgésico del tramadol no está mediado por receptores opiáceos en el dolor en ratones en el postoperatorio inmediato. Brazilian Journal of Anesthesiology (Edición en Espanol). 2015; 65(3):186-190.
  111. 5- Ruoff G, Rosenthal N, Jordan D, Karim R, Kamin M. Tramadol/Acetaminophen combination tablets for the treatment of chronic lower back pain: A multicenter, randomized, double-blind, placebo-controlled outpatient study. Clin Ther. 2003; 25(4):1123-1141
  112. Perrot S, Krause D, Crozes P, Naïm C. Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in patients with subacute low back pain: A multicenter, randomized, double-blind, parallel-group, 10-day treatment study. Clin Ther. 2006; 28(10):1592-1606
  113. Candiotti K, Gitlin M. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?. Curr Med Res Opin. 2010; 26(7):1677-1684
  114. Schröder W, Vry J, Tzschentke T, Jahnel U, Christoph T. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain. 2010; 14(8):814-821
  115. Hartrick CT, Rozek RJ. Tapentadol in pain management: A mu-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs. 2011; 25(5):359-70.
  116. Tzschentke TM, Jahnel U, Kogel B, et al. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc). 2009; 45(7):483-96.
  117. Tzschentke TM, Terlinden R, et al. Tapentadol HCl. Drugs Future. 2006; 31(1):1053-61.
  118. Schroder W, Tzschentke T, Terlinden R et al. Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia. J Pharmacolog Exp Ther. 2011; 337(1):312-320.
  119. Christoph T, De Vry J, Tzschentke T. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Neurosci Lett. 2010; 470(2):91-94.
  120. Steigerwald I, Müller M, Davies A et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin. 2012; 28(6):911-936
  121. Baron R, Likar R, Martin-Mola E et al. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study. Pain Pract. 2015; 16(5):580-599.
  122. Baron R, Martin-Mola E, Müller M, Dubois C, Falke D, Steigerwald I. Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study. Pain Pract. 2014; 15(5):455-470
  123. Gálvez R, Schäfer M, Hans G, Falke D, Steigerwald I. Tapentadol Prolonged Release Versus Strong Opioids for Severe, Chronic Low Back Pain: Results of an Open-Label, Phase 3b Study. Adv Ther. 2013; 30(3):229-259
  124. Cepeda M, Fife D, Kihm M, Mastrogiovanni G, Yuan Y. Comparison of the Risks of Shopping Behavior and Opioid Abuse Between Tapentadol and Oxycodone and Association of Shopping Behavior and Opioid Abuse. Clin J Pain. 2014; 30(12):1051-1056
  125. Langford R, Knaggs R, Farquhar-Smith P, Dickenson A. Is tapentadol different from classical opioids? A review of the evidence. Br J Pain. 2016; 10(4):217-221.
  126. Dart R, Surratt H, Le Lait M, et al. Diversion and Illicit Sale of Extended Release Tapentadol in the United States. Pain Medicine. 2015; 17(8):1490-1496.
  127. Tzschentke TM. NA and 5-HT reuptake inhibitors and alpha-2 agonists. En: Analgesics: From Chemistry and Pharmacology to Clinical Application. Buschmann H, Christoph T, Friderichs E, Maul C and Sundermann B, eds. 1a ed. Weinheim: Wiley-VCH; 2002:264-284.
  128. Wild J, Grond S, Kuperwasser B et al. Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain. Pain Pract. 2010; 10(5):416-427.
  129. Afilalo M, Etropolski M, Kuperwasser B, et al. Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee. Clin Drug Investig. 2010; 30(8):489-505
  130. Buynak R, Shapiro D, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 2010; 11(11):1787-1804
  131. Schwartz S, Etropolski M, Shapiro D et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011; 27(1):151-162.
  132. Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010; 27(6):381-399.
  133. Max B. Antidepressants as analgesics. En: Fields HL, Liebeskind JC, eds. Progress in pain research and management. 1a ed. Seattle: IASP Pub; 1994:229-246.
  134. Barutell C, Ribera MV. Medicación coadyuvante. Dolor. 2000; 15(1):199-206.
  135. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2005; 20(3):1-75
  136. Max M, Culnane M, Schafer S, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987; 37(4):589-589
  137. Attal N, Cruccu G, Haanpää M et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006; 13(11):1153-1169.
  138. Goldstein D, Lu Y, Detke M, Lee T, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005; 116(1):109-118.
  139. Pritchett YL, McCarberg BH, Watkin JG, Robinson MJ. Duloxetine for the management of diabetic peripheral neuropathic pain: Response profile. Pain Med. 2007; 8(5):397-409
  140. Rowbotham M, Goli V, Kunz N, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004; 110(3):697-706
  141. Goldenberg D. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumat. 2007; 21(3):499-511.
  142. Harden RN. Chronic Neuropathic Pain Mechanisms, Diagnosis, and Treatment. Neurologist. 2005; 11(2):111-122
  143. Vinik A, Strotmeyer E, Nakave A, Patel C. Diabetic Neuropathy in Older Adults. Clin Geriatr Med. 2008; 24(3):407-435
  144. Guevara-Lopez U, Covarrubias-Gomez A, Garcia-Ramos G, Hernandez-Jimenez S. Parámetros de práctica para el manejo del dolor neuropático. Revista de investigación clínica. 2006; 58(2):126-138.
  145. Keskinbora K, Pekel A, Aydinli I. Gabapentin and an Opioid Combination Versus Opioid Alone for the Management of Neuropathic Cancer Pain: A Randomized Open Trial. J Pain Symptom Manage. 2007; 34(2):183-189
  146. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuripathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998; 280(21):1831-1836
  147. Ben-Menachem E. Pregabalin Pharmacology and Its Relevance to Clinical Practice. Epilepsia. 2004; 45(Supl. 6):13-18
  148. Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain celular GABA, glutamate, and glutamine concentrations. Seizure. 2003; 12(5):300-306
  149. Horga JF, Horga A. Pregabalin: new therapeutic contributions of calcium channel alpha2delta protein ligands on epilepsy and neuropathic pain. Rev Neurol. 2006; 42(4):223-37
  150. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week randomised, double-blind, multicentre, placebo-controlled trial of flexible-and-fixed-dose regimens. Pain. 2005; 115(3):254-263
  151. Freeman R, Durso-De Cruz E, Emir B. Efficacy, safety, and tolerability of pregablin treatment for painful diabetic peripheral neuropathy. Findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008; 31(7):1448-54.
  152. McKenna TJ. Glucocorticoid Therapy. En: Pinchera A, ed. Endocrinology and Metabolism. 4ª ed. Berkshire: McGraw-Hill; 2001: 329-336.
  153. Galofré JC. Manejo de los corticoides en la práctica clínica. Rev Med Universitaria Navarra. 2009; 53(9):9-18
  154. Neira F, Ortega L. Revisión del tratamiento con corticoides en el dolor de espalda según la medicina basada en la evidencia. Rev Soc Esp Dolor. 2009; 16(6):352-369.
  155. Conn A, Buenaventura RM, Datta S, Abdi S, Diwan S. Systematic review of caudal epidural injections in the management of chronic low back pain. Pain Physician. 2009; 12(1):109-135
  156. Posner JB. Back pain and epidural spinal cord compression. Med Clin North Am. 1987; 71(2):185-205
  157. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003; 43(Supl. 1):S16-24
  158. Torres JC. Toxina botulínica A: mecanismo de acción en el manejo del dolor. Rev Iberoamericana del Dolor. 2007; 4:32-40.
  159. Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localitation and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol. 1986; 103(2):521-534
  160. Thant ZS, Tan EK. Emerging therapeutic applications of botulinum toxin. Med Sci Monit. 2003; 9(2):40-48
  161. De Rungs D, Víctor A, Robles M. Baclofeno un agonista GABA B y su administración para mejorar el comportamiento del dolor neuropático en ratas. Revista Mexicana de Anestesiología. 2016; 39(1):20-29.
  162. Knotkova H, Pappagallo M. Adjuvant Analgesics. Med Clin North Am. 2007; 91(1):113-124
  163. Mathias CJ, Witkinson A, Lewis PS, Peart WS, Sever PS, Snell ME. Clonidine lowers blood pressure independently of renin supression in patients with unilateral renal artery stenosis. Chest. 1983; 83(Supl. 2):357-359
  164. Buvanendran A, Reuben S, Kroin J. Recent advances in nonopioid analgesics for acute pain management. Techniques in Regional Anaesthesia and Pain Management. 2007; 11(1):19-26.
18 de 18